Cardiff Oncology, Inc. (CRDF) stock
CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.85−0.04 (-4.46%)
Close on Nov 20, 2026Market cap $66.34MP/E –Yield –
Cardiff Oncology r&d expenses
Research and development expenses are spending on new products and technology.
Cardiff Oncology's R&D Expenses for the twelve months ending Jun 30, 2026 was $25.95M, down 37.3% year over year. For fiscal 2025 it was $35.33M, down 4.1% from the year before. Over ten years it grew 12.8% a year on average. The highest annual figure on record is $36.85M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.33M | -4.1% |
| FY2024 | Dec 31, 2024 | $36.85M | +12.2% |
| FY2023 | Dec 31, 2023 | $32.86M | +21.2% |
| FY2022 | Dec 31, 2022 | $27.11M | +56.0% |
| FY2021 | Dec 31, 2021 | $17.38M | +54.7% |
| FY2020 | Dec 31, 2020 | $11.24M | +0.7% |
| FY2019 | Dec 31, 2019 | $11.16M | +36.7% |
| FY2018 | Dec 31, 2018 | $8.16M | +3.6% |
| FY2017 | Dec 31, 2017 | $7.88M | -47.5% |
| FY2016 | Dec 31, 2016 | $15.01M | +41.7% |
| FY2015 | Dec 31, 2015 | $10.59M | +59.0% |
| FY2014 | Dec 31, 2014 | $6.66M | +68.8% |
| FY2013 | Dec 31, 2013 | $3.95M | +105.6% |
| FY2012 | Dec 31, 2012 | $1.92M | +110.9% |
| FY2011 | Dec 31, 2011 | $910.69K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.92M | -48.9% |
| Q1 FY2026 | Mar 31, 2026 | $6.77M | -35.4% |
| Q4 FY2025 | Dec 31, 2025 | $5.08M | -47.7% |
| Q3 FY2025 | Sep 30, 2025 | $8.20M | -15.0% |
| Q2 FY2025 | Jun 30, 2025 | $11.58M | +22.0% |
| Q1 FY2025 | Mar 31, 2025 | $10.48M | +30.8% |
| Q4 FY2024 | Dec 31, 2024 | $9.71M | +25.1% |
| Q3 FY2024 | Sep 30, 2024 | $9.64M | +20.2% |
| Q2 FY2024 | Jun 30, 2024 | $9.49M | +18.4% |
| Q1 FY2024 | Mar 31, 2024 | $8.01M | -11.5% |
| Q4 FY2023 | Dec 31, 2023 | $7.76M | +20.5% |
| Q3 FY2023 | Sep 30, 2023 | $8.02M | +33.5% |
| Q2 FY2023 | Jun 30, 2023 | $8.02M | +7.7% |
| Q1 FY2023 | Mar 31, 2023 | $9.05M | +25.6% |
| Q4 FY2022 | Dec 31, 2022 | $6.44M | +10.6% |
| Q3 FY2022 | Sep 30, 2022 | $6.01M | +44.7% |
| Q2 FY2022 | Jun 30, 2022 | $7.45M | +80.8% |
| Q1 FY2022 | Mar 31, 2022 | $7.21M | +119.8% |
| Q4 FY2021 | Dec 31, 2021 | $5.82M | +82.1% |
| Q3 FY2021 | Sep 30, 2021 | $4.15M | +45.5% |
| Q2 FY2021 | Jun 30, 2021 | $4.12M | +66.4% |
| Q1 FY2021 | Mar 31, 2021 | $3.28M | +21.2% |
| Q4 FY2020 | Dec 31, 2020 | $3.20M | +11.7% |
| Q3 FY2020 | Sep 30, 2020 | $2.86M | +1.3% |
| Q2 FY2020 | Jun 30, 2020 | $2.48M | -12.5% |
| Q1 FY2020 | Mar 31, 2020 | $2.71M | +2.2% |
| Q4 FY2019 | Dec 31, 2019 | $2.86M | +14.7% |
| Q3 FY2019 | Sep 30, 2019 | $2.82M | +54.0% |
| Q2 FY2019 | Jun 30, 2019 | $2.83M | +44.9% |
| Q1 FY2019 | Mar 31, 2019 | $2.65M | +40.6% |
| Q4 FY2018 | Dec 31, 2018 | $2.50M | +107.0% |
| Q3 FY2018 | Sep 30, 2018 | $1.83M | +29.4% |
| Q2 FY2018 | Jun 30, 2018 | $1.95M | +98.9% |
| Q1 FY2018 | Mar 31, 2018 | $1.88M | -56.0% |
| Q4 FY2017 | Dec 31, 2017 | $1.21M | -68.1% |
| Q3 FY2017 | Sep 30, 2017 | $1.41M | -64.1% |
| Q2 FY2017 | Jun 30, 2017 | $981.72K | – |
| Q1 FY2017 | Mar 31, 2017 | $4.28M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.78M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.94M | – |
See a number that looks wrong?